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Abstract
Background: Globally, cancer is generally recognized as a developmental threat yet most countries in Africa lack
capacity to diagnose cancer especially gynecological cancers resulting in late detection and poor outcomes.
However, most studies on gynecological cancers in Africa tend to focus on cervical cancer compared to the other
gynecological cancers. Therefore, this scoping review will aim to describe the existing literature on the
epidemiological burden of ovarian, endometrial, vaginal, and vulva cancers, their risk factors, and potential
screening methods/techniques in Africa to identify priority research gaps for further research to inform health
policy decisions.
Methods: The framework promulgated by Arksey and O’Malley and improved by Levac et al. will be used as a
guide for this scoping review. A comprehensive search for relevant published studies in PubMed, CINAHL, SCOPUS,
Google Scholar, and ScienceDirect with no date limitation to the last search date. The database search strategy will
include keywords, Boolean operators, and medical subject heading terms. We will additionally consult the WHO/
IARC website, IHME/Global Burden of Disease Study. A snowball approach will also be used to search the reference
list of all included studies to obtain relevant papers for possible inclusion in this review. We will include articles that
involve African countries, focused on ovarian, endometrial, vaginal, and vulva cancers, their risk factors, and
potential screening methods/techniques in any language. We will exclude studies on cervical cancer and other
cancers as well as review articles. The abstracts and full-text selection will be conducted by two independent
reviewers using this review’s eligibility criteria as a guide. All the review selection tools, and the data extraction form
will be pilot tested for accuracy and consistency. The data will be organized into thematic areas, summarized and
the results communicated narratively.
Discussion: It is anticipated that this review will reveal important literature gaps to guide future research to inform
health policy decisions about ovarian, endometrial, and rare gynecological neoplasms in Africa. This review’s
findings will be disseminated via peer review journals, conferences, and other social media such Twitter and
LinkedIn.
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Background
Cancer is generally recognized as a threat to global de-
velopment. In 2017, the global incidence and deaths due
to cancer were estimated to be approximately 24.5 mil-
lion cases and 9.6 million deaths respectively [1]. Cancer
is part of the emerging non-communicable diseases in
Africa with an ever-increasing burden on individuals,
communities, and healthcare systems. A higher number
of people die from cancers compared to acquired im-
munodeficiency syndrome, tuberculosis, and malaria
combined [2]. Cancer (including gynecological cancers)
hitherto was thought to be a disease of the affluent par-
ticularly those in high-income countries, but there are
indications that the burden of cancer is rising in low-
and-middle-income countries (LMICs) despite facing
diagnostic challenges [2]. In 2018, the global cancer inci-
dence, mortality, and prevalence, number (GLOBOCAN)
report showed a steady rise in the occurrence of
gynecological cancers in LMICs [3].
Gynecological cancers include cervical cancer, endo-
metrial cancer, ovarian and fallopian tube cancers, can-
cer of the vagina, and cancer of the vulva. Primary
vaginal cancer is relatively rare but is associated with
HIV infection which is highly prevalent in Africa [4].
Most vaginal cancers are secondary, but chronic human
papillomavirus (HPV) infections which are rife in Africa
results in primary vaginal cancer [4, 5]. Vulva cancer
also relatively rare has a causal relationship with chronic
oncogenic HPV infections and preventive strategies
aimed at cervical cancer has benefits for vulva cancer [6,
7]. Endometrial cancer is the third commonest
gynecological cancer in LMICs [2]. The risk factors of
these cancers may include a sedentary lifestyle, obesity,
unopposed estrogen, infertility, and decreased fertility
rates [8, 9]. With a growing westernization in the life-
style of Africans, these risk factors are increasingly be-
coming important in the continent. Ovarian cancer with
about 18.8% representation of all gynecological cancers
in LMICs [3] is characterized by a high case fatality rate
because it is largely asymptomatic until the late stages of
the disease [10]. Fallopian tube cancers have similar
characteristics with ovarian cancers and are classified by
the International Federation of Gynaecology and Obstet-
rics together with ovarian cancers [10].
A prior review indicated an increasing burden of
gynecological cancers in LMICs due to a rise in cervical
cancer incidence [11]. In 2013, Iyoke and Ugwu con-
ducted a review and reported that 60% of gynecological
cancers in these countries which are mostly found in Af-
rica are due to cervical cancer [11]. The highest incidence
and mortality of cervical cancers occur in African coun-
tries [4] mostly due to the absence of effective national
preventive strategies in these countries [11]. Together with
vaginal cancer and cancer of the vulva, cervical cancer is
highly preventable with vaccination against the highly
oncogenic HPV species [4, 6, 7, 12]. However, poor diag-
nostic abilities in most African countries coupled with
general poor health-seeking behavior is likely to hamper
early detection and desired treatment outcomes of cancer
including most gynecological cancers. Although several
gynecological cancers exist, much attention has been given
to cervical cancer compared to the others particularly in
Africa due to known reasons including diagnostic chal-
lenges. Nonetheless, research on the other gynecological
neoplasms such as ovarian, endometrial, and other rare
gynecological neoplasms is essential. Several previous re-
views have been published in the past relating to
gynecological cancer screening [11, 13–15] but to date,
the range of research and knowledge gaps on ovarian,
endometrial, vaginal, and vulva cancers in Africa is not
known. Therefore, we propose to conduct a scoping re-
view to describe evidence about gynecological cancers in
Africa focusing on the epidemiological burden of ovarian,
endometrial, vaginal, and vulva cancers, their risk factors,
and potential screening methods/techniques. We antici-
pate that this review will reveal important literature gaps
to inform future research to inform health policy decisions
about ovarian, endometrial, and rare gynecological neo-
plasms in Africa.
Methods
Overview of the study
Scoping reviews aim to map rapidly the key concepts
underpinning a research area and the main sources and
types of evidence available. Scoping reviews also involve
the synthesis and analysis of a wide range of research and
non-research material to provide greater conceptual clar-
ity about a specific topic or field of evidence [16–18].
Scoping reviews aim to provide a map of what evidence
has been produced from disparate or heterogeneous
sources as opposed to seeking only the best evidence to
answer a particular question related to policy or practice
[18]. This review will be based on the 2005 Arksey and
O’Malley framework as reviewed and enhanced by Levac
and colleagues in 2010 [19–21]. This protocol stipulates 5
mandatory and 1 optional steps as follows: identification
of research question; identification of relevant studies;
study selection; charting of data, collating, summarizing
and reporting the results; and the optional step of consult-
ation [20–22]. This protocol is reported according to the
Preferred Reporting Items for Systematic Reviews and
Meta-Analysis Protocol (PRISMA-P) statement [23].
However, the resulting paper will be reported per the
PRISMA extension for Scoping Reviews checklist [21].
Identifying the research question
Our overall scoping review question will be: What
evidence exists on ovarian, endometrial, vaginal, and
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vulva cancer research in Africa? The population, con-
cept, and context (PCC) mnemonic (Table 1) was used
to determine the eligibility of the review question. The
secondary research questions include:
 What evidence exists on the epidemiological burden
(morbidity, incidence, prevalence, and mortality) of
ovarian, endometrial, vaginal, and vulva cancers in
Africa?
 What evidence exists on the risk factors of ovarian,
endometrial, vaginal, and vulva cancers in Africa?
 What evidence exists on potential screening
techniques/methods/recommendations for ovarian,
endometrial, vaginal, and vulva cancers in Africa?
Information sources and search strategy
A comprehensive search for relevant published articles
on gynecological cancers in Africa will be conducted in
the following databases: PubMed/MEDLINE, CINAHL,
Web of science, SCOPUS, Google Scholar, and Science-
Direct without date limitation to the last search date.
The search will include the use of a combination of rele-
vant keywords and index terms with appropriate Bool-
ean operators (AND/OR). Medical Subject Headings
(MeSH) terms or subject heading in all fields will be in-
cluded and syntax modified appropriately for each data-
base if necessary, to enable identification of all relevant
studies. Study design and publication language limita-
tions will be removed during the search. An electronic
pilot search strategy for this review is illustrated in
Table 2. Nonetheless, the authors will consult an experi-
enced librarian to improve the search strategy if needed.
We will also consult the websites of the WHO/Inter-
national Agency for Research on Cancer, Institute for
Health Metrics and Evaluation/Global Burden of Disease
Study. A snowball approach will further be used to
search the reference list of all included articles to obtain
relevant articles for possible inclusion in this review. A
detailed searched record will be documented as follows:
date of search, search engine used, keywords used in the
search, the number of retrieved publications, and the
number of eligible studies found. The principal investi-
gator (SYN) who is an expert obstetrician and
gynecologist will conduct the search in the electronic da-
tabases. Mendeley Desktop reference manager will be
used to compile all the articles deemed relevant for this
review.
Study selection and eligibility criteria
Study selection
The principal investigator (SYN) will conduct an exten-
sive title screening guided by this review’s eligibility cri-
teria and all eligible studies imported to a folder created
in Mendeley reference manager for this scoping review
study. The library created will be cleaned by identifying
and removing duplicate articles before the abstract
screening phase. Subsequently, the cleaned library will
be shared among the review team. SYN and MAM will
independently screen the abstract and full text using the
eligibility criteria for the review. Disagreements between
SYN and MAM responses shall be resolved by dialog
and consensus-building. DK will serve as an arbiter at
the full-text screening stage if any disagreement arises
between SYN and MAM. In the case where a full-text
article cannot be retrieved or is not accessible from the
online databases, assistance will be sought from the
Catholic University College library or the Stellenbosch
University to obtain it for screening. We will also con-
sider writing to the authors to request any full-text art-
icle not accessible freely online if needed. Finally, this
review will adopt the PRISMA flow chart [22, 23] (Fig. 1)
to account for the articles at each stage of the screening.
Eligibility criteria of this review
Inclusion criteria This will include the following:
 Studies that involved African countries
 Studies that include human participants (women)
 Studies that include ovarian, endometrial, vaginal,
and vulva cancers
 Studies reporting on the epidemiological burden
(morbidity, incidence, prevalence, and mortality) of
ovarian, endometrial, vaginal, and vulva cancers
 Studies that reported findings on the risk factors of
ovarian, endometrial, vaginal, and vulva cancers
 Primary study designs (quantitative, qualitative, and
mixed methods studies)
Exclusion criteria This will include the following:
 Studies that focused on other gynecological cancers
such as cervical cancer
 Studies that focused on other types of cancer such
as breast cancer




C-Concept Gynecological neoplasms: This will include ovarian, endometrial, vaginal, and vulva cancers
C-Context The epidemiological burden (incidence, morbidity, prevalence, and mortality); risks factors; and potential screening methods/
techniques in African countries
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 Studies focus on the natural science of ovarian,
endometrial, vaginal, and vulva cancers
 Studies focusing on the diagnostic and/
management/treatment of ovarian, endometrial,
vaginal, and vulva cancers
 Studies focusing on the economic burden of ovarian,
endometrial, vaginal, and vulva cancers
 Gray literature, conference papers, opinions,
editorials, theses, dissertations, and unpublished
studies
 Articles without full text
Charting the data
We will extract all the germane findings from the in-
cluded articles aimed at answering the main scoping re-
view question. Two reviewers (SYN and MAM) will
independently pilot the data extraction form using 10
percent of the included studies to ensure consistency
and uniformity. Appropriate adjustments will conse-
quently be made for final use. The data extraction form
will be updated regularly until all relevant and applicable
information has been extracted. The data extraction
form will include the following:
 Author and publication year
 Study title
 Aim/objective of the study
 Geographical location of the study (country)
 Type of study design
 Study setting (such as facility-based, community-
based, others)
 Number of study participants
 Mean age/range of study population (women)
 Targeted gynecological cancer
 Burden (incidence, prevalence, morbidity, mortality)
 Reported risk factors per the type of gynecological
cancer investigated
 Potential screening techniques/methods/
recommendations
 Relevant recommendations/conclusions
Collating, summarizing, and reporting the results
Thematic content analysis will be employed to describe
the themes that are related to this review’s objective.
The thematic analysis would ensure the identification of
all the themes essential to address the research question.
The sub-themes will be collated and structured around
the following main themes: the epidemiological burden
Table 2 Pilot search for the review conducted on PubMed




PubMed (((((“Gynecological cancer”[MeSH Terms]) OR “cervical cancer”[MeSH Terms]) OR “endometrial cancer”[MeSH
Terms]) OR “ovarian cancer”[MeSH Terms]) OR “fallopian tube cancers”[MeSH Terms]) OR “cancer of the
vagina”[MeSH Terms]) OR “cancer of the vulva”[MeSH Terms]) OR “screening service”[MeSH Terms]) OR
“screening”[MeSH Terms]) AND africa) OR “angola”[MeSH Terms] OR “angola”[All Fields]) OR (“benin”[MeSH Terms]
OR “benin”[All Fields])) OR (“botswana”[MeSH Terms] OR “botswana”[All Fields])) OR (“burkina faso”[MeSH Terms]
OR (“burkina”[All Fields] AND “faso”[All Fields]) OR “burkina faso”[All Fields])) OR (“burundi”[MeSH Terms] OR
“burundi”[All Fields])) OR (“cameroon”[MeSH Terms] OR “cameroon”[All Fields])) OR (“cabo verde”[MeSH Terms] OR
(“cabo”[All Fields] AND “verde”[All Fields]) OR “cabo verde”[All Fields] OR (“cape”[All Fields] AND “verde”[All Fields])
OR “cape verde”[All Fields])) OR (“central african republic”[MeSH Terms] OR (“central”[All Fields] AND “african”[All
Fields] AND “republic”[All Fields]) OR “central african republic”[All Fields])) OR (“chad”[MeSH Terms] OR “chad”[All
Fields])) OR (“comoros”[MeSH Terms] OR “comoros”[All Fields])) AND (“congo”[MeSH Terms] OR “congo”[All
Fields])) OR (“cote d'ivoire”[MeSH Terms] OR (“cote”[All Fields] AND “d'ivoire”[All Fields]) OR “cote d'ivoire”[All
Fields])) OR (“djibouti”[MeSH Terms] OR “djibouti”[All Fields])) OR (“equatorial guinea”[MeSH Terms] OR
(“equatorial”[All Fields] AND “guinea”[All Fields]) OR “equatorial guinea”[All Fields])) OR (“eritrea”[MeSH Terms] OR
“eritrea”[All Fields])) OR (“ethiopia”[MeSH Terms] OR “ethiopia”[All Fields])) OR (“gabon”[MeSH Terms] OR
“gabon”[All Fields])) OR (“gambia”[MeSH Terms] OR “gambia”[All Fields] OR “the gambia”[All Fields])) OR
(“ghana”[MeSH Terms] OR “ghana”[All Fields])) OR (“guinea”[MeSH Terms] OR “guinea”[All Fields])) OR (“guinea-
bissau”[MeSH Terms] OR “guinea-bissau”[All Fields] OR (“guinea”[All Fields] AND “bissau”[All Fields]) OR “guinea
bissau”[All Fields])) OR (“kenya”[MeSH Terms] OR “kenya”[All Fields])) OR (“lesotho”[MeSH Terms] OR “lesotho”[All
Fields])) OR (“liberia”[MeSH Terms] OR “liberia”[All Fields])) OR (“madagascar”[MeSH Terms] OR “madagascar”[All
Fields])) OR (“malawi”[MeSH Terms] OR “malawi”[All Fields])) OR (“mali”[MeSH Terms] OR “mali”[All Fields])) OR
(“mauritania”[MeSH Terms] OR “mauritania”[All Fields])) OR (“mauritius”[MeSH Terms] OR “mauritius”[All Fields])) OR
(“mozambique”[MeSH Terms] OR “mozambique”[All Fields])) OR (“namibia”[MeSH Terms] OR “namibia”[All Fields]))
OR (“niger”[MeSH Terms] OR “niger”[All Fields])) OR (“nigeria”[MeSH Terms] OR “nigeria”[All Fields])) OR
(“rwanda”[MeSH Terms] OR “rwanda”[All Fields])) OR (“sao tome and principe”[MeSH Terms] OR (“sao”[All Fields]
AND “tome”[All Fields] AND “principe”[All Fields]) OR “sao tome and principe”[All Fields])) OR (“senegal”[MeSH
Terms] OR “senegal”[All Fields])) OR (“seychelles”[MeSH Terms] OR “seychelles”[All Fields])) OR (“sierra leone”[MeSH
Terms] OR (“sierra”[All Fields] AND “leone”[All Fields]) OR “sierra leone”[All Fields])) OR (“somalia”[MeSH Terms] OR
“somalia”[All Fields])) OR (“south africa”[MeSH Terms] OR (“south”[All Fields] AND “africa”[All Fields]) OR “south
africa”[All Fields])) OR (“sudan”[MeSH Terms] OR “sudan”[All Fields])) OR (“eswatini”[MeSH Terms] OR “eswatini”[All
Fields] OR “swaziland”[All Fields])) OR (“tanzania”[MeSH Terms] OR “tanzania”[All Fields])) OR (“togo”[MeSH Terms]
OR “togo”[All Fields])) OR (“uganda”[MeSH Terms] OR “uganda”[All Fields])) OR (“zambia”[MeSH Terms] OR
“zambia”[All Fields])) AND (“zimbabwe”[MeSH Terms] OR “zimbabwe”[All Fields]) AND (“2013/01/01”[PubDate] :
“2020/12/31”[PubDate])
15538
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(incidence, morbidity, prevalence, and mortality) of ovar-
ian, endometrial, vaginal, and vulva cancers in Africa;
and the reported risk factors of ovarian, endometrial,
vaginal, and vulva cancers in Africa; and potential
screening methods/techniques for ovarian, endometrial,
vaginal, and vulva cancers in Africa. This review will also
analyze other relevant emerging themes. Subsequently,
we will summarize the findings and a narrative account
for each theme or outcome reported. A map will be used
to show the geographical locations of the included stud-
ies. Graphs and tables will also be used to present the
study characteristics such as the study designs, and
others where possible. If feasible, a follow-up meta-
analysis using quantitative data from this review will be
considered due to the qualitative nature of scoping re-
view studies.
Discussion
This scoping review study aims to describe the existing
literature on the epidemiological burden of ovarian,
endometrial, vaginal, and vulva cancers, their risk
factors, and potential screening methods/techniques in
Africa. Cancer is a global health problem and remains a
threat to development but many countries in low-and-
middle-income countries (LMICs) lack capacity to diag-
nose most cancers including gynecological cancers
which often result in late detection and poor outcomes.
Research relating to gynecological cancers in many
LMICs tends to focus more on cervical cancer although
several other gynecological cancers exist. Knowledge of
the range of evidence or research activity on the other
gynecological cancers aside from cervical cancer is es-
sential to help identify priority research gaps for future
research to facilitate health policy decisions, hence, the
need for this review. Due to lack of external funding, this
review will be limited to African countries only though
the inclusion of other LMICs would have been great.
Similarly, we will not cover research on diagnostic and/
management/treatment of ovarian, endometrial, vaginal,
and vulva cancers as well as other rare gynecological
cancers. The evidence obtained from this review will be
disseminated via publication on several platforms includ-
ing peer-reviewed journals, conferences, and interactions
with potential knowledge users.
Fig. 1 PRISMA 2009 flow diagram
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